Bexsero: Provides active immunization against invasive meningococcal disease caused by 3 strains of Neisseria meningitidis serogroup B (strains prevalent in the US).
Tremenba: Provides active immunization against invasive meningococcal disease caused by 4 strains of Neisseria meningitidis serogroup B (strains prevalent in the US).
Action⬆⬇
Induces production of antibodies to several strains of serogroup B Neisseria meningitidis.
Therapeutic effects:
Prevention of invasive meningococcal disease.
Pharmacokinetics⬆⬇
Absorption: Well absorbed following IM administration.
Distribution: Unknown.
Metabolism/Excretion: Unknown.
Half-Life: Unknown.
Time/Action Profile⬆⬇
(antibody response)
ROUTE
ONSET
PEAK
DURATION
IM
within 2 mo
unknown
unknown
Contraind./Precautions⬆⬇
Contraindicated in:
Severe allergic reaction to a previous dose;
Latex allergy (Bexsero tip caps contain latex).
Use Cautiously in:
Geri: Safe and effective use in patients >65 yr has not been established;
Lactation: Use cautiously if breastfeeding;
OB: Use during pregnancy only if clearly needed;
Pedi: Safe and effective use in children <10 yr not established (>90% risk of fever in infants <12 mo).
IM (Adults and Children 10–25 yr): Two 0.5 mL doses one mo apart.
Trumenba
IM (Adults and Children 10–25 yr): 0.5 mL followed by a second dose 2 mo later and a third dose 4 mo after the second dose.
Availability⬆⬇
Suspension for IM injection (Bexsero tip caps contain latex): 0.5 mL in pre-filled syringes
Assessment⬆⬇
Monitor for signs and symptoms of allergic reaction (dyspnea, rash, hives, swelling of face, lips, or throat). Keep epinephrine, an antihistamine, and resuscitation equipment close by in the event of an anaphylactic reaction.
Assess for latex allergy. Bexsero tip cap contains latex.
Assess for syncope. Make patient is sitting or lying down during and immediately following injections.
Implementation⬆⬇
IM: Shake syringe vigorously for a homogenous white suspension; do not use if solution has separated, discolored, or contains particulate matter. Administer 0.5 mL IM into deltoid muscle of upper arm. Do not mix with other vaccines in same syringe.
Patient/Family Teaching⬆⬇
Explain purpose of vaccine to patient/parent. Emphasize need for 2 doses of immunization series for Bexseroor 3 doses for Tremenba.
Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.
Evaluation/Desired Outcomes⬆⬇
Prevention of invasive meningococcal disease including meningitis.
US Brand Names⬆⬇
Bexsero, Trumenba
Code⬆
NDC Code
0005- Wyeth Pharmaceutical Division of Wyeth Holdings LLC
0005-0100- Trumenba
0005-0100-02- 1 SYRINGE in 1 CARTON (0005-0100-02) / .5 mL in 1 SYRINGE (0005-0100-01)
0005- Wyeth Pharmaceutical Division of Wyeth Holdings LLC
0005-0100- Trumenba
0005-0100-05- 5 SYRINGE in 1 CARTON (0005-0100-05) / .5 mL in 1 SYRINGE (0005-0100-01)
0005- Wyeth Pharmaceutical Division of Wyeth Holdings LLC
0005-0100- Trumenba
0005-0100-10- 10 SYRINGE in 1 CARTON (0005-0100-10) / .5 mL in 1 SYRINGE (0005-0100-01)